Advertisement

Gene Therapy Arrives in Europe

The European Commission approves the Western hemisphere’s first gene therapy, aimed at correcting a lipid-processing disorder.

By | November 6, 2012

stock.xchng, tijman.The field of gene therapy has a long but frustrating history, with early safety concerns that threatened to shutter its clinical development altogether. Now, almost 10 years after China sanctioned the world’s first gene therapy in 2003, the strategy has arrived in Europe. (There are still no approved gene therapies in the United States.)

Approved last week (November 2) by the European Commission, uniQure’s Glybera utilizes viral vectors to deliver DNA encoding a lipid-processing enzyme to patients lacking a functional copy due to a gene mutation. The therapy, which is indicated for patients with severe symptoms such as life-threatening bouts of pancreatitis, will be sold in Europe beginning in late 2013.

“It’s really a milestone that this product has been approved,” said Katherine High, a pediatrician at the University of Pennsylvania and Children’s Research Hospital of Philadelphia, who was not involved in research on Glybera. It marks the first time that a gene therapy has been “judged safe and efficacious for human clinical use,” according to regulatory standards used in Europe and the United States, she noted.

“It’s really an important moment for people with rare inherited diseases,” said Sam Wadsworth, head of gene therapy research and development at biotech company Genzyme. “A new therapeutic modality has opened up.” Wadsworth, who was closely following Glybera’s path to approval, expects that the approval will smooth the way for other gene therapies in development, including those at Genzyme.

The concept of gene therapy is relatively straightforward: identify diseases that result from mutated genes, and replace the defective genes with working copies to correct the ailment. Viral vectors are an easy way to introduce new genes into infected cells. But this strategy can be risky. Retroviral vectors, which integrate their genes into host genomes, have been linked to gene therapy-induced leukemia, and in 1999, teenager Jessie Gelsinger died after his body mounted a massive immune response to the adenovirus vector used in a strategy to combat his liver disease. (Read more in The Scientist’s June feature, “Targeting DNA.”)

Glybera was developed by Amsterdam-based uniQure for patients suffering from a rare lipid-processing disease, called lipoprotein lipase deficiency (LPLD), that affects only one or two people in a million. LPLD is caused by loss-of-function mutations in the liproprotein lipase (LPL) gene, critical for metabolism of dietary long-chain fatty acids. Normally, these long-chain fatty acids are packaged into triglyceride bundles to help transport lipids from the gut to other tissues, where LPL then cleaves the bundles into sizes that cells can handle. In LPLD patients, the enzyme can’t cleave the bundles. As a result, dietary fat is poorly absorbed by cells and remains in the blood. “It looks like you dumped half a liter of crème fraiche into the bloodstream,” said uniQure CEO Jörn Aldag.

LPLD patients experience recurrent bouts of pancreatitis, an extraordinarily painful and sometimes life-threatening condition wherein the digestive enzymes usually secreted in small and safe forms are activated at once, and begin digesting the pancreas and surrounding tissues. LPLD patients also have extraordinarily high blood triglyceride levels, which predisposes them to early-onset diabetes and atherosclerosis. Currently, the disease can only be addressed by reducing dietary fat to extremely low levels and making up the difference with special oils comprised of medium chain fatty acids, which aren’t packaged into bundles for transport.

Glybera relies on adeno-associated virus (AAV) to deliver a functional copy of the LPL gene to skeletal muscle. AAV has several qualities that make it an attractive gene therapy vehicle, noted Jude Samulski, director of the University of North Carolina, Chapel Hill’s Gene Therapy Center, who pioneered use of AAV as a gene therapy vector in the early 1980s. AAV DNA rarely integrates into the host genome, reducing the risk of prompting cancerous mutations upon gene integration. Instead, the virus becomes latent, persisting as an extrachromosomal piece of DNA. Also, because AAV is not pathogenic to humans “we didn’t have to remove pathogenic components to turn it into a vector,” explained Samulski, who was not involved in research on Glybera. (See a graphical representation of how AAV and other viral vectors deliver their gene packages.)

To make use of the AAV vector, Glybera’s developers stripped out the viral genes and replaced 96 percent of the AAV genome with therapeutic DNA—including the LPL gene and a promoter and regulatory elements from other viruses. They also added proteins that direct the vectors to skeletal muscle.

In two Phase II/III clinical trials, LPLD patients received a series of injections into the thigh muscle, followed by several weeks of immunosuppressive drugs to blunt immune responses to the viral capsids—the cause of Gelsinger’s untimely death. The treatment successfully reduced triglyceride levels in blood for up to 12 weeks after injection, and drastically reduced incidence of pancreatitis attacks for up to 2 years after treatment. Patients were even able to relax their dietary restrictions, also helping to increase quality of life, said André Carpentier, an endocrinologist at the Université de Sherbrooke in Québec, who collaborated on one of Glybera’s clinical trials. And, most importantly, anotable side effect has been reported only once so far—a fever that resolved within 12 hours.

The approval by the European Medicines Agency certifies that Glybera is effective and safe, presenting minimal risk of tumorgenicity and immunogenecity, said Aldag. UniQure is in the process of applying for approval from the US Food and Drug Administration and is also looking to bring Glybera to Korea, Israel, and countries in South America.

Researchers are hopeful that Glybera’s approval is the first of many. Other AAV-based gene therapies in development include those for hemophilia and retinal degeneration, and gene therapies for Parkinson’s disease and muscular dystrophy are also in clinical trials.

“Intuitively, it will probably make it easier to get the next gene therapy approved,” said Samulski. “The whole community learns about evaluating and regulating the new drug.”

Advertisement

Add a Comment

Avatar of: You

You

Processing...
Processing...

Sign In with your LabX Media Group Passport to leave a comment

Not a member? Register Now!

LabX Media Group Passport Logo

Comments

Avatar of: mlerman

mlerman

Posts: 22

November 7, 2012

I am glad gene therapy is a reality now. My only concern is the use of the AAV as a vehicle despite the assumption that it "rarely integrates into the host genome". EU has already developed better non integrating episomal vectors. Michael Lerman, M.D.,Ph.D.

Avatar of: robertkotin

robertkotin

Posts: 1

November 7, 2012

This is exciting news and uniQure management and scientists deserve praise for their efforts. The achievements of uniQure were enabled by the company adapting a novel and innovative rAAV production platform  that baculovirus and inverteberate cells. These methodologies and materials were developed at the NIH and adapted into a cGMP process by uniQure.

Avatar of: kpetrak

kpetrak

Posts: 8

November 7, 2012

This is an interesting use of gene therapy as an intra-muscular "depot" delivery system for providing the body with LPLD enzyme for upto 12 weeks after injection. I wonder whether even better, and perhaps safer results could be achieved by formulating an intra-muscular slow-release depot system for LPLD (based on physical control of LPLD diffusion), or perhaps by using a device for delivering LPLD into the system (such as are being used for delivering insulin in a controlled fashion). 

Avatar of: Dr Ichha Purak

Dr Ichha Purak

Posts: 15

November 8, 2012

Gene therapy can be used as a significant tool to cure some genetic diseases

 

Avatar of: CRoss

CRoss

Posts: 1

December 12, 2012

The idea of a slow release depot would be great, except the LPL enzyme is not very stable, with a half-life of only minutes in blood. In this case, gene therapy was the only option. - Colin Ross

Avatar of: Cheaptrx

Cheaptrx

Posts: 51

December 17, 2012

I have fun read this blog post. TRX suspesion trainerI want to see

 more about this topic.TRX for saleThank you for publishing this 

quality information.Anyhow, I’m likely to subscribe to your rss as

 well as I wish you make good articles again soon.

http://www.trxforsalex.com/

http://www.trxforsale2012.com/

Avatar of: Jillian

Jillian

Posts: 1

February 5, 2013

Well I hope we don't get too carried away with this gene therapy thing as it wont take some lunatic long to start with some outlandish experimentation. For the better development of mankind "Yes", to tamper with other un-realities "No".

I want to see it used for the better, to understand and cure diseases etc; but not to boost some Scientist's ego....or to create some over-exercised freak of nature

Follow The Scientist

icon-facebook icon-linkedin icon-twitter icon-vimeo icon-youtube
Advertisement

Stay Connected with The Scientist

  • icon-facebook The Scientist Magazine
  • icon-facebook The Scientist Careers
  • icon-facebook Neuroscience Research Techniques
  • icon-facebook Genetic Research Techniques
  • icon-facebook Cell Culture Techniques
  • icon-facebook Microbiology and Immunology
  • icon-facebook Cancer Research and Technology
  • icon-facebook Stem Cell and Regenerative Science
Advertisement
Advertisement
The Scientist
The Scientist